Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of the preservative-free
fixed-dose combination of tafluprost and timolol (FDC) to concomitant administration of
tafluprost and timolol.
This study will enroll patients who have ocular hypertension or glaucoma.
The study schedule includes seven visits to the study site and three stages:
- washout of 5 days to 4 weeks depending on current glaucoma medication (if any)
- 6-month study treatment period
- 1-3 weeks post-study period